Related references
Note: Only part of the references are listed.Enhancement of antioxidant defense mechanism by pitavastatin and rosuvastatin on obesity-induced oxidative stress in Wistar rats
Javed A. Ansari et al.
TOXICOLOGY MECHANISMS AND METHODS (2012)
Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat
Rostislav Vecera et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2011)
Soybean glycinin improves HDL-C and suppresses the effects of rosuvastatin on hypercholesterolemic rats
Priscila G. Fassini et al.
LIPIDS IN HEALTH AND DISEASE (2011)
Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia
Michael S. Kostapanos et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2010)
Nutritional Status Affects Fluvastatin-Induced Hepatotoxicity and Myopathy in Rats
Junko Sugatani et al.
DRUG METABOLISM AND DISPOSITION (2010)
Rhabdomyolysis Induced by Rosuvastatin and Sildenafil
Giovanni Pennisi et al.
SOUTHERN MEDICAL JOURNAL (2010)
In vivo and In vitro Drug Interactions Study of Glimepride with Atorvastatin and Rosuvastatin
V. J. Galani et al.
JOURNAL OF YOUNG PHARMACISTS (2010)
Effect of the HMG-CoA Reductase Inhibitor Rosuvastatin on Early Chronic Kidney Injury in Obese Zucker Rats Fed With an Atherogenic Diet
Efrain Reisin et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2009)
Evaluation of the binding orientations of testosterone in the active site of homology models for CYP2C11 and CYP2C13
Hongwu Wang et al.
BIOCHEMICAL PHARMACOLOGY (2009)
New Insights into the Structural Features and Functional Relevance of Human Cytochrome P450 2C9. Part I
Sui-Lin Mo et al.
CURRENT DRUG METABOLISM (2009)
Differences in hepatic expression of genes involved in lipid homeostasis between hereditary hypertriglyceridemic rats and healthy Wistar rats and in their response to dietary cholesterol
J. Orolin et al.
FOOD AND CHEMICAL TOXICOLOGY (2009)
Elevated warfarin metabolism in warfarin-resistant roof rats (Rattus rattus) in Tokyo
Mayumi Ishizuka et al.
DRUG METABOLISM AND DISPOSITION (2007)
Direct and indirect interactions between, antidepressant drugs and CYP2C6 in the rat liver during long-term treatment
W. A. Daniel et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2006)
Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects
D Jindal et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics
SG Simonson et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Myalgia, hyper-CK-aemia, and hypocoagulability in a patient under rosuvastatin and warfarin
J Finsterer et al.
EUROPEAN JOURNAL OF NEUROLOGY (2005)
Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation
I Locatelli et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2005)
Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily
E Barbosa-Sicard et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-Leiden mice
DJM Delsing et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2005)
Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat
K Nezasa et al.
XENOBIOTICA (2002)
Share Paper
